Novel carboxamide derivatives
By developing selective Kv7.2 enhancer compounds, the shortcomings of existing drugs in regulating Kv7.2 channels have been overcome, enabling effective treatment and prevention of related diseases, improving neural network stability, alleviating symptoms, and slowing disease progression.
Patent Information
- Application Number
- CN202480042158.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-08
- Publication Date
- 2026-01-20
AI Technical Summary
Existing drugs have failed to effectively regulate the Kv7.2 channel, resulting in untreated related diseases such as epilepsy, autism, and intellectual disability. Furthermore, existing Kv7.2 modulators suffer from insufficient selectivity and pharmacological properties.
To develop Kv7.2 enhancer compounds with selective and favorable pharmacological properties to enhance the activity of Kv7.2 channels, and to prepare corresponding pharmaceutical compositions and kits for the treatment of Kv7.2-related disorders, diseases or disabilities.
By enhancing Kv7.2 channel activity, improving neural network stability, reducing abnormal neural activity, providing therapeutic and preventative treatment effects, alleviating disease symptoms, improving quality of life, and slowing disease progression.
Smart Images

Figure CN121368581A_ABST
Abstract
Citation Information
Patent Citations
Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them
US5384330A
1-((2-(2,2,2-trifluoroethoxy)pyridin-4-YL)methyl)urea derivatives as KCNQ potentiators
WO2020163268A1